Literature DB >> 17062381

Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy.

Ole B Suhr1, Per Lindqvist, Bert-Ove Olofsson, Anders Waldenström, Christer Backman.   

Abstract

Heart complications are frequently encountered in hereditary transthyretin amyloidosis. Lately, reports of late onset familial amyloid polyneuropathy (FAP) cases presenting with a phenotype similar to that observed in senile systemic amyloidosis have emerged. The aim of the present study was to evaluate morphological and functional features of the heart by echocardiography including myocardial strain measurements, and to compare the outcome for early with those of late onset FAP cases. Eighty-one biopsy and genetically proven FAP, ATTR Val30Met patients were investigated with two-dimensional, M-mode echocardiography and myocardial strain with special attention to inter-ventricular septum (IVS) thickness. IVS thickness was closely related to the age at onset (P < 0.0001), but not to duration of disease. Seventeen percent of the patients had severe left ventricular hypertrophy (IVS > 15 mm). These patients were all late onset cases and represented 39% of all of the late onset cases. Strain measurements were also closely related to IVS thickness and age at onset thereby signifying a decreased function of the heart muscle in late onset cases. From the present investigation it appears that late onset Swedish FAP-cases more readily develop cardiomyopathy with an increased IVS thickness. Different pathways for amyloid formation in the heart may operate in early and late onset cases.

Entities:  

Mesh:

Year:  2006        PMID: 17062381     DOI: 10.1080/13506120600876849

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  13 in total

Review 1.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

2.  Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries.

Authors:  Rosa Lauppe; Johan Liseth Hansen; Anna Fornwall; Katarina Johansson; Mark H Rozenbaum; Anne Mette Strand; Merja Väkeväinen; Johanna Kuusisto; Einar Gude; J Gustav Smith; Finn Gustafsson
Journal:  ESC Heart Fail       Date:  2022-05-12

Review 3.  Epidemiology and clinical manifestations of cardiac amyloidosis.

Authors:  Farhan Bajwa; Ryan O'Connor; Karthikeyan Ananthasubramaniam
Journal:  Heart Fail Rev       Date:  2021-10-25       Impact factor: 4.654

Review 4.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

Review 5.  Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies.

Authors:  Rabah Alreshq; Frederick L Ruberg
Journal:  Curr Opin Cardiol       Date:  2021-05-01       Impact factor: 2.161

6.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460

7.  (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.

Authors:  Björn Pilebro; Ole B Suhr; Ulf Näslund; Per Westermark; Per Lindqvist; Torbjörn Sundström
Journal:  Ups J Med Sci       Date:  2016-02-05       Impact factor: 2.384

Review 8.  Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Authors:  Yesim Parman; David Adams; Laura Obici; Lucía Galán; Velina Guergueltcheva; Ole B Suhr; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

9.  Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.

Authors:  Sandra Arvidsson; Björn Pilebro; Per Westermark; Per Lindqvist; Ole B Suhr
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

10.  Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.

Authors:  Louise-Laure Mariani; Pierre Lozeron; Marie Théaudin; Zoia Mincheva; Aissatou Signate; Beatrice Ducot; Vincent Algalarrondo; Christian Denier; Clovis Adam; Guillaume Nicolas; Didier Samuel; Michel S Slama; Catherine Lacroix; Micheline Misrahi; David Adams
Journal:  Ann Neurol       Date:  2015-10-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.